GlucoTrack Inc Dossier
Qualitative Analysis
Business overview
Glucotrack, Inc. (formerly Integrity Applications, Inc.) is a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes. The company's primary product candidate is the Glucotrack Continuous Blood Glucose Monitor (CBGM), a long-term implantable system designed to continually measure blood glucose levels directly from a blood vessel with zero lag time. Unlike traditional continuous glucose monitors (CGMs) that measure glucose in interstitial fluid, Glucotrack's intravascular approach aims to eliminate measurement lag and remove the requirement for an additional on-body wearable component. The device is designed to offer a sensor longevity of up to 3 years with minimal calibration.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the fully implantable Continuous Blood Glucose Monitor (CBGM) system into U.S. clinical evaluation. This includes securing a U.S. clinical trial site, engaging a specialized diabetes Medtech Clinical Research Organization (CRO), and preparing for study initiation in the second half of 2026 pending FDA approval.
Expected impact: Establishes the clinical safety and performance profile of the CBGM system in the U.S. market, serving as a precursor to a pivotal trial for FDA commercial approval.
Securing and expanding patent protection for the core technologies of the CBGM platform, including proprietary sensor chemistry, intravascular lead design, and low-power electronics.
Expected impact: Strengthens competitive barriers and protects the company's proprietary technology as it moves toward commercialization.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborated on computational modeling to evaluate and optimize the enzyme longevity of Glucotrack's implantable electrochemical sensors, demonstrating a projected sensor lifespan of over three years.
Terms: Not publicly disclosed.
Provides a flexible equity financing facility of up to $20.0 million to support ongoing operations, clinical trials, and working capital needs.
Terms: Glucotrack may sell up to $20.0 million of common stock over the term of the agreement. As of April 27, 2026, 760,000 shares had been sold for net proceeds of $712,976.